DOI: http://dx.doi.org/10.18203/2349-3933.ijam20160969

Clinical profile and outcome of urinary tract infection caused by extended spectrum beta-lactamase producing Escherichia coli in critically ill patients in a tertiary care hospital in South India: a case control study

Jayaprakash Subramani, Anand Janagond

Abstract


Background: Infections with Extended spectrum beta-lactamase (ESBL) producing organisms have been associated with poor outcome. Our aim of this study is to compare clinical profile of Urinary tract infection (UTI) caused by ESBL producing Escherichia coli (E. coli) with Non-ESBL producing E. coli.

Methods: Retrospective analysis of patients admitted in Intensive care unit in a tertiary care hospital was done. 50 Patients with ESBL producing E. coli infection were assigned as cases; 50 Patients with Non-ESBL producing E. coli were assigned as controls. Clinical characteristics of UTI caused by both ESBL & non-ESBL producing E. coli in critically ill patients and their clinical outcome were observed. Mortality risk on admission was calculated using sepsis scoring system.

Results: Most patients in both groups were in 6th and 7th decade. Male to female ratio in both groups were almost similar. Incidence of complications was higher in ESBL group. Mortality rate was 10% in ESBL group; 4% in Non-ESBL group. Mean duration of ICU stay was 4.2 days (ESBL) and 3.1 days (Non-ESBL). APACHE IV and SOFA scoring system mortality prediction accuracy was 60% in both groups.

Conclusions: Initiation of empirical therapy with carbapenem antibiotics on admission in critically ill with UTI showed significant impact on mortality. Mean duration of ICU stay in ESBL group was longer than non-ESBL group which is statistically significant. Mortality risk was predicted by APACHE IV & SOFA scores on admission with good accuracy.


Keywords


ESBL producing E. coli, Urinary tract infection, APACHE IV score, SOFA score

Full Text:

PDF

References


Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinico-radiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160(6):797-805.

Chen SL, Jackson SL, Boyko EJ. Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models. J Urol. 2009;182(6):S51-6.

Rodrı´guez-Ban˜o J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43:1407-14.

Gregory B, Fishman NO, Patel JB, Paul HE, Ebbing L. Extended-Spectrum Lactamase producing Escherichia coli and Klebsiella species: Risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol. 2002;23:254-60.

Valverde A. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during non-outbreak situations in Spain. J Clin Microbiol. 2004;42:4769-75.

Emily SB, Myrna TM. Prevalence and risk factors associated with extended spectrum beta lactamase (ESBL) production among selected Enterobacteriaceae isolates at the Philippine General Hospital. Philippine J Microbiol Infect Dis. 2003;32.

Kim YK, Pai H, Lee HJ. Bloodstream infections by extended spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002;46:1481-91.

Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enerobacteriaceae. Drugs. 2003;63:353-65.

Mario T, Teresa S, Maurizio S. Bloodstream infections caused by extended-spectrum β-lactamase producing Klebsiella pneumoniae: Risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50:498-504.

Paterson DL, Bonomo RA. Extended-spectrum â-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-86.

Garnacho-Montero. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Critical Care Medicine. 2003;31(12):2742-51.

Typpo KV, Petersen NJ, Hallman DM, Markovitz BP, Mariscalco MM. Day one MODS is associated with poor functional outcome and mortality in the pediatric intensive care unit. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intens Crit Care Soc. 2009;10(5):562-70.

Shanthi M, Sekar U. Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella Pneumoniae: Risk Factors for Infection and impact of resistance on outcomes. J Assoc Physicians of India. 2010;58:41-3.

Denis B, Lafaurie M, Donay JL, Fontaine JP, Oksenhendler E, Raffoux E et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. Intern J Infect Dis. 2015;39:1-6.

Dahhan T, Jamil M, Al-Tarifi A, Abouchala N, Kherallah M. Validation of the APACHE IV scoring system in patients with severe sepsis and comparison with the APACHE II system. Crit Care. 2009;13(1):P511.